Labcorp (LH) Competitors

78.0% of Medpace shares are held by institutional investors. Comparatively, 95.9% of Labcorp shares are held by institutional investors. 20.5% of Medpace shares are held by insiders. Comparatively, 0.8% of Labcorp shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Medpace has a beta of 1.18, meaning that its stock price is 18% more volatile than the broader market. Comparatively, Labcorp has a beta of 0.9, meaning that its stock price is 10% less volatile than the broader market.

Labcorp has higher revenue and earnings than Medpace. Labcorp is trading at a lower price-to-earnings ratio than Medpace, indicating that it is currently the more affordable of the two stocks.

Medpace presently has a consensus target price of $467.08, suggesting a potential downside of 11.38%. Labcorp has a consensus target price of $308.00, suggesting a potential upside of 13.20%. Given Labcorp's stronger consensus rating and higher possible upside, analysts clearly believe Labcorp is more favorable than Medpace.

Medpace has a net margin of 17.19% compared to Labcorp's net margin of 6.66%. Medpace's return on equity of 120.89% beat Labcorp's return on equity.

In the previous week, Labcorp had 8 more articles in the media than Medpace. MarketBeat recorded 11 mentions for Labcorp and 3 mentions for Medpace. Medpace's average media sentiment score of 1.22 beat Labcorp's score of 0.99 indicating that Medpace is being referred to more favorably in the media.

Labcorp has higher revenue and earnings than AMN Healthcare Services. AMN Healthcare Services is trading at a lower price-to-earnings ratio than Labcorp, indicating that it is currently the more affordable of the two stocks.

Labcorp has a net margin of 6.66% compared to AMN Healthcare Services' net margin of -0.95%. AMN Healthcare Services' return on equity of 18.01% beat Labcorp's return on equity.

95.9% of Labcorp shares are held by institutional investors. Comparatively, 99.2% of AMN Healthcare Services shares are held by institutional investors. 0.8% of Labcorp shares are held by company insiders. Comparatively, 1.1% of AMN Healthcare Services shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, Labcorp had 1 more articles in the media than AMN Healthcare Services. MarketBeat recorded 11 mentions for Labcorp and 10 mentions for AMN Healthcare Services. Labcorp's average media sentiment score of 0.99 beat AMN Healthcare Services' score of 0.29 indicating that Labcorp is being referred to more favorably in the media.

Labcorp presently has a consensus price target of $308.00, indicating a potential upside of 13.20%. AMN Healthcare Services has a consensus price target of $27.00, indicating a potential downside of 17.19%. Given Labcorp's stronger consensus rating and higher possible upside, equities analysts clearly believe Labcorp is more favorable than AMN Healthcare Services.

Labcorp has a beta of 0.9, suggesting that its stock price is 10% less volatile than the broader market. Comparatively, AMN Healthcare Services has a beta of 0.44, suggesting that its stock price is 56% less volatile than the broader market.

Labcorp has a net margin of 6.66% compared to Bio-Rad Laboratories' net margin of 6.52%. Labcorp's return on equity of 16.29% beat Bio-Rad Laboratories' return on equity.

In the previous week, Labcorp had 8 more articles in the media than Bio-Rad Laboratories. MarketBeat recorded 11 mentions for Labcorp and 3 mentions for Bio-Rad Laboratories. Labcorp's average media sentiment score of 0.99 beat Bio-Rad Laboratories' score of 0.82 indicating that Labcorp is being referred to more favorably in the media.

Labcorp has a beta of 0.9, meaning that its share price is 10% less volatile than the broader market. Comparatively, Bio-Rad Laboratories has a beta of 1.08, meaning that its share price is 8% more volatile than the broader market.

Labcorp has higher revenue and earnings than Bio-Rad Laboratories. Labcorp is trading at a lower price-to-earnings ratio than Bio-Rad Laboratories, indicating that it is currently the more affordable of the two stocks.

Labcorp presently has a consensus price target of $308.00, suggesting a potential upside of 13.20%. Bio-Rad Laboratories has a consensus price target of $303.33, suggesting a potential upside of 1.06%. Given Labcorp's stronger consensus rating and higher possible upside, equities research analysts plainly believe Labcorp is more favorable than Bio-Rad Laboratories.

95.9% of Labcorp shares are owned by institutional investors. Comparatively, 65.2% of Bio-Rad Laboratories shares are owned by institutional investors. 0.8% of Labcorp shares are owned by insiders. Comparatively, 30.3% of Bio-Rad Laboratories shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

95.9% of Labcorp shares are owned by institutional investors. Comparatively, 87.2% of Cardinal Health shares are owned by institutional investors. 0.8% of Labcorp shares are owned by company insiders. Comparatively, 0.1% of Cardinal Health shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Cardinal Health has higher revenue and earnings than Labcorp. Labcorp is trading at a lower price-to-earnings ratio than Cardinal Health, indicating that it is currently the more affordable of the two stocks.

Labcorp currently has a consensus target price of $308.00, suggesting a potential upside of 13.20%. Cardinal Health has a consensus target price of $246.93, suggesting a potential upside of 3.80%. Given Labcorp's higher possible upside, equities research analysts clearly believe Labcorp is more favorable than Cardinal Health.

Labcorp has a net margin of 6.66% compared to Cardinal Health's net margin of 0.62%. Labcorp's return on equity of 16.29% beat Cardinal Health's return on equity.

In the previous week, Labcorp had 9 more articles in the media than Cardinal Health. MarketBeat recorded 11 mentions for Labcorp and 2 mentions for Cardinal Health. Cardinal Health's average media sentiment score of 1.07 beat Labcorp's score of 0.99 indicating that Cardinal Health is being referred to more favorably in the news media.

Labcorp pays an annual dividend of $2.88 per share and has a dividend yield of 1.1%. Cardinal Health pays an annual dividend of $2.04 per share and has a dividend yield of 0.9%. Labcorp pays out 25.5% of its earnings in the form of a dividend. Cardinal Health pays out 31.2% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Cardinal Health has increased its dividend for 29 consecutive years. Labcorp is clearly the better dividend stock, given its higher yield and lower payout ratio.

Labcorp has a beta of 0.9, suggesting that its share price is 10% less volatile than the broader market. Comparatively, Cardinal Health has a beta of 0.52, suggesting that its share price is 48% less volatile than the broader market.